FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to gastroenterology and hepatology. It can be used for prediction of liver cirrhosis in patients with chronic hepatitis C. Patient's blood serum enzyme immunoassay is used to determine the quantitative values of osteopontin and hepatocyte growth factor. If observing values of osteopontin above 23 ng/ml and hepatocyte growth factor above 935 ng/ml, a risk of developing hepatic cirrhosis is predicted.
EFFECT: method is non-invasive, accessible, provides the timely selection of the optimal approach to the antifibrotic therapy.
2 cl, 6 dwg, 9 tbl, 4 ex
